Critical Limb Ischemia Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Critical Limb Ischemia Market

Critical Limb Ischemia Market Summary

According to DelveInsight, there were about 2.44 million diagnosed cases of Critical Limb Ischemia (CLI) in the 7MM in 2023, a number projected to rise by 2034. The US accounted for the largest market size at USD 1,367 million in 2023, expected to grow further. Current treatments include standard of care, Ranger Drug-coated Balloon, and SeQuent Please OTW, with standard of care dominating the market (~USD 1,845 million in 2023). Collategene, once conditionally approved in Japan, has been discontinued. The emerging therapy ACP-01 is expected to launch between 2026 to 2028, potentially reducing the Critical Limb Ischemia disease burden.

DelveInsight’s report, “Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast–2034,” offers a comprehensive analysis of Critical Limb Ischemia, covering historical and projected epidemiology along with market trends across the US, EU5 (Germany, Spain, Italy, France, and the UK), and Japan. The study highlights current treatment practices, upcoming therapies, market share of key drugs, and Critical Limb Ischemia market size from 2020–2034 across seven major markets. It also examines treatment algorithms, market drivers and barriers, unmet needs, and growth opportunities to evaluate the market’s future potential.

Request for a Free Sample Report @ Critical Limb Ischemia Market Forecast

Some facts of the Critical Limb Ischemia Market Report are:

• According to DelveInsight, the Critical Limb Ischemia market size in USA was USD 1,367 million in 2023.
• Leading Critical Limb Ischemia companies working in the market are Boston Scientific Corporation, AnGes, Inc., Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Inc, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, BioGenCell Ltd., Abbott Medical Devices and others.
• Key Critical Limb Ischemia Therapies expected to launch in the market are REX-001, Temsirolimus Adventitial Delivery, Collategene, ACP-01, Honedra (CLBS12), RJX (Rejuveinix), YQ23, BGC101, Esprit BTK Device, and others.
• In March 2025: Shockwave Medical launched the Javelin peripheral IVL catheter in the United States, reporting 99% procedural success in heavily calcified BTK lesions typical of CLI.
• In March 2025: The FDA approved the first generic rivaroxaban 2.5 mg tablets to reduce major cardiovascular events in PAD, broadening access for CLI patients requiring antithrombotic therapy.
• In February 2025: Teleflex completed the EUR 760 million (USD 890 million) acquisition of Biotronik’s vascular intervention unit, adding drug-coated balloons and stents directed at CLI limb-salvage markets.
• In October 2024, Surmodics, Inc. (Nasdaq: SRDX), a prominent medical device and in vitro diagnostics company, announced that it had received FDA 510(k) clearance for its PounceTM XL Thrombectomy System.
• In April 2024, Abbott re-entered the bioabsorbable stent space with FDA approval for its Esprit BTK System-a drug-eluting scaffold designed to reopen below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease.
• In March 2024, Elixir Medical received FDA Breakthrough Device Designation for its DynamX® BTK System, an adaptive implant designed to treat below-the-knee (BTK) vessel blockages in patients with chronic limb-threatening ischemia (CLTI).
• In March 2024, BIOTRONIK received FDA Breakthrough Device Designation for its FreesolveTM below-the-knee resorbable magnesium scaffold (BTK RMS), designed for chronic limb-threatening ischemia (CLTI) patients. CLTI, the most severe form of peripheral artery disease (PAD), affects 11% of the 200 million PAD sufferers worldwide and is linked to high amputation rates, mortality, and healthcare costs.In February 2024, Cell Biopeutics Resources Sdn Bhd announced results of an Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.

Critical Limb Ischemia Overview

Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD) characterized by chronic ischemic rest pain, non-healing wounds, or gangrene in the limbs. Critical Limb Ischemia symptoms include persistent pain in the feet or toes, ulcers, and tissue loss, often leading to severe mobility issues or amputation if left untreated. Critical Limb Ischemia causes typically stem from advanced atherosclerosis, where narrowed arteries restrict blood flow to the extremities. Critical Limb Ischemia diagnosis involves physical examination, ankle-brachial index (ABI), imaging techniques like duplex ultrasound, CT angiography, or MR angiography to assess blood flow and vascular blockages. Early Critical Limb Ischemia detection is essential for preventing complications and improving limb salvage rates.

Critical Limb Ischemia treatment focuses on restoring adequate blood flow through medical management, endovascular procedures, or surgical revascularization. In advanced cases, Critical Limb Ischemia management may also require wound care, pain control, and risk factor modification such as smoking cessation and diabetes management. Critical Limb Ischemia prognosis is poor without timely intervention, emphasizing the need for awareness and early care. Ongoing Critical Limb Ischemia research is exploring novel therapies to improve outcomes and reduce the risk of major amputations, enhancing quality of life for affected patients.

Learn more about Critical Limb Ischemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Critical Limb Ischemia Treatment Market

Critical Limb Ischemia Market Outlook

The Critical Limb Ischemia (CLI) therapeutics market in the 7MM is projected to evolve between 2020 and 2034. In 2023, the US dominated the market, representing approximately 74% of the total 7MM market. Within Europe, Germany had the largest market (~USD 136 million), while Spain had the smallest (~USD 58 million). Japan accounted for USD 51 million, about 3% of the 7MM market. The anticipated launch of emerging therapies, such as ACP-01, is expected to further influence market growth in the coming years.

Critical Limb Ischemia Market Drivers

• Rising Prevalence: Increasing cases of peripheral artery disease (PAD) and diabetes, which are major risk factors for CLI, drive market demand.
• Aging Population: Higher CLI incidence in older adults, especially those above 60–70 years, boosts therapy needs.
• Advancements in Therapies: Development of novel treatments such as ACP-01, Ranger Drug-coated Balloon, and regenerative therapies is expanding options beyond standard care.
• Improved Diagnostics: Enhanced imaging and biomarker-based diagnostics allow earlier detection and intervention.
• Regulatory Support: Orphan drug designations and fast-track approvals encourage innovation and investment.
• Unmet Medical Need: High rates of amputations and limited effective therapies create strong demand for innovative treatments.

Critical Limb Ischemia Market Barriers

• High Treatment Costs: Advanced therapies, especially cell-based treatments, are expensive and may limit accessibility.
• Late-Stage Diagnosis: Many patients are diagnosed at advanced CLI stages, reducing treatment effectiveness.
• Complexity of Disease: Variation in severity (Rutherford stages) complicates standardization of therapy.
• Clinical Trial Challenges: Small patient populations and diverse disease presentation make trial recruitment and design difficult.
• Limited Awareness: Lack of awareness among patients and clinicians can delay diagnosis and intervention.
• Reimbursement Hurdles: Coverage for novel therapies may be restricted, slowing adoption in key markets.

Download the report to understand which factors are driving Critical Limb Ischemia market trends @ Critical Limb Ischemia Market Outlook

Critical Limb Ischemia Treatment Market

Management of CLI often involves a multifaceted approach, with the primary goal of restoring blood flow to the affected limb. This typically begins with lifestyle modifications such as smoking cessation and maintaining a healthy diet. Medications, such as antiplatelet agents and anticoagulants, are commonly prescribed to reduce blood clotting and improve circulation. Additionally, minimally invasive procedures like angioplasty and stenting can be utilized to open blocked arteries and enhance blood flow. In more advanced cases, surgical options such as bypass grafting may be necessary to reroute blood around the blockage, thereby salvaging the limb.

Close monitoring and follow-up care are integral aspects of CLI treatment, as the condition requires ongoing management to prevent recurrence and monitor for potential complications. Patients often undergo rehabilitation programs to improve mobility and reduce the risk of further vascular issues. In severe instances where limb preservation is not feasible, amputation may be considered as a last resort. Through a combination of medical therapies, interventions, and lifestyle adjustments, clinicians strive to improve quality of life, enhance limb function, and mitigate the serious consequences associated with Critical Limb Ischemia.

Critical Limb Ischemia Epidemiology

In 2023, the United States accounted for the highest total diagnosed cases of Critical Limb Ischemia (CLI), with approximately 1,341 thousand cases, a number expected to increase in the coming years. Among European countries, Germany had the highest diagnosed cases (~311 thousand), followed by Italy (~202 thousand), while Spain recorded the lowest (~131 thousand). Japan reported around 122 thousand diagnosed cases, representing roughly 5% of the 7MM total. In the US, age-specific prevalence was highest among individuals aged 80–84 (~321 thousand), followed by 60–69 (~310 thousand) and 50–59 (~263 thousand). In Japan, severity-specific cases were predominantly Rutherford 5 (~79 thousand), followed by Rutherford 4 (~26 thousand) and Rutherford 6 (~17 thousand).

Critical Limb Ischemia Epidemiology Segmentation

• Diagnosed Prevalent Cases of Critical Limb Ischemia
• Gender-specific Diagnosed Prevalent Cases of Critical Limb Ischemia
• Age-specific Diagnosed Prevalent Cases of Critical Limb Ischemia
• Severity-specific Diagnosed Prevalent Cases of Critical Limb Ischemia

Explore more about Critical Limb Ischemia Epidemiology @ Critical Limb Ischemia Patient Pool Forecasting and Prevalence

Critical Limb Ischemia Pipeline Development Activities and Drugs Uptake

ACP-01 (Hemostemix Inc.)

ACP-01 is an autologous cell therapy for Critical Limb Ischemia (CLI), using patient-derived angiogenic cell precursors to promote blood vessel formation and tissue repair, potentially preventing amputations. Phase II trials completed by 2020 demonstrated significant ulcer reduction and lower amputation and mortality rates. ACP-01 remains in Hemostemix’s pipeline for CLI treatment.

HONEDRA® (Lisata Therapeutics, Japan)

HONEDRA® is a regenerative medicine for CLI and Buerger’s disease, aiming to improve blood flow and prevent severe complications. Phase II studies in Japan have shown promising efficacy and safety, with ongoing discussions with the PMDA and efforts to secure a local partner for regulatory approval.

Critical Limb Ischemia Therapeutics Assessment

Major key companies are working proactively in the Critical Limb Ischemia Therapeutics market to develop novel therapies which will drive the Critical Limb Ischemia treatment markets in the upcoming years are Boston Scientific Corporation (NYSE: BSX), AnGes, Inc. (TYO: 4563), Mitsubishi Tanabe Pharma (TYO: 4508), B. Braun Melsungen AG, Medtronic Endovascular (NYSE: MDT), Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc. (TSXV: HEM), Caladrius Biosciences (NASDAQ: CLBS), Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd. (Private), Abbott Medical Devices (NYSE: ABT) and others.

Learn more about the emerging Critical Limb Ischemia therapies & key companies @ Critical Limb Ischemia Clinical Trials and FDA Approvals

Critical Limb Ischemia Report Key Insights

1. Critical Limb Ischemia Patient Population

2. Critical Limb Ischemia Market Size and Trends

3. Key Cross Competition in the Critical Limb Ischemia Market

4. Critical Limb Ischemia Market Dynamics (Key Drivers and Barriers)

5. Critical Limb Ischemia Market Opportunities

6. Critical Limb Ischemia Therapeutic Approaches

7. Critical Limb Ischemia Pipeline Analysis

8. Critical Limb Ischemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Critical Limb Ischemia Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Critical Limb Ischemia Competitive Intelligence Analysis

4. Critical Limb Ischemia Market Overview at a Glance

5. Critical Limb Ischemia Disease Background and Overview

6. Critical Limb Ischemia Patient Journey

7. Critical Limb Ischemia Epidemiology and Patient Population

8. Critical Limb Ischemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Critical Limb Ischemia Unmet Needs

10. Key Endpoints of Critical Limb Ischemia Treatment

11. Critical Limb Ischemia Marketed Products

12. Critical Limb Ischemia Emerging Therapies

13. Critical Limb Ischemia Seven Major Market Analysis

14. Attribute Analysis

15. Critical Limb Ischemia Market Outlook (7 major markets)

16. Critical Limb Ischemia Access and Reimbursement Overview

17. KOL Views on the Critical Limb Ischemia Market

18. Critical Limb Ischemia Market Drivers

19. Critical Limb Ischemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services